JP2016500647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500647A5 JP2016500647A5 JP2015520069A JP2015520069A JP2016500647A5 JP 2016500647 A5 JP2016500647 A5 JP 2016500647A5 JP 2015520069 A JP2015520069 A JP 2015520069A JP 2015520069 A JP2015520069 A JP 2015520069A JP 2016500647 A5 JP2016500647 A5 JP 2016500647A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- decoy peptide
- acid residues
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 11
- 102000005681 phospholamban Human genes 0.000 claims 10
- 108010059929 phospholamban Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 102000005569 Protein Phosphatase 1 Human genes 0.000 claims 3
- 108010059000 Protein Phosphatase 1 Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 2
- DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 claims 2
- QEDGNYFHLXXIDC-DCAQKATOSA-N Met-Pro-Gln Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O QEDGNYFHLXXIDC-DCAQKATOSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000006957 competitive inhibition Effects 0.000 claims 2
- 230000030609 dephosphorylation Effects 0.000 claims 2
- 238000006209 dephosphorylation reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000003913 calcium metabolism Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010247 heart contraction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668034P | 2012-07-05 | 2012-07-05 | |
| US61/668,034 | 2012-07-05 | ||
| PCT/KR2013/006009 WO2014007584A1 (en) | 2012-07-05 | 2013-07-05 | Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500647A JP2016500647A (ja) | 2016-01-14 |
| JP2016500647A5 true JP2016500647A5 (https=) | 2016-04-21 |
| JP6404213B2 JP6404213B2 (ja) | 2018-10-10 |
Family
ID=49882272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520069A Active JP6404213B2 (ja) | 2012-07-05 | 2013-07-05 | ホスホランバンのプロテインホスファターゼ１媒介の脱リン酸化抑制用デコイペプチド｛ＤｅｃｏｙＰｅｐｔｉｄｅｓＩｎｈｉｂｉｔｉｎｇＰｒｏｔｅｉｎＰｈｏｓｐｈａｔａｓｅ１−ＭｅｄｉａｔｅｄＤｅｐｈｏｓｐｈｏｒｙｌａｔｉｏｎｏｆＰｈｏｓｐｈｏｌａｍｂａｎ｝ |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | USRE48636E1 (https=) |
| EP (1) | EP2870171B1 (https=) |
| JP (1) | JP6404213B2 (https=) |
| KR (1) | KR101516791B1 (https=) |
| ES (1) | ES2639121T3 (https=) |
| WO (1) | WO2014007584A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530278A4 (en) * | 2016-10-24 | 2019-10-30 | Gwangju Institute of Science and Technology | COMPOSITION WITH PROTEIN-PHOSPHATASE-1-INHIBITING PEPTIDE FOR THE TREATMENT OF VASCULAR DISEASES |
| KR20240173703A (ko) * | 2023-06-05 | 2024-12-13 | (주)벳바젠 | 포스포람반의 단백질 포스파타아제 1-매개 탈인산화 억제용 데코이 펩타이드를 암호화하는 뉴클레오타이드 및 ccn5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000025804A2 (en) * | 1998-11-02 | 2000-05-11 | The Regents Of The University Of California | A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| US20040121942A1 (en) | 1999-11-02 | 2004-06-24 | Kenneth Chien | Method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| US20040214760A1 (en) * | 2001-01-15 | 2004-10-28 | Ramesh Gupta | Inhibition pf protein-phosphatases for the treatment of heart failure |
| US7989606B2 (en) | 2006-02-10 | 2011-08-02 | The University Of Cincinnati | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
| WO2008137681A2 (en) | 2007-05-02 | 2008-11-13 | Intrexon Corporation | Pp1 ligands |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US9046530B2 (en) * | 2011-12-02 | 2015-06-02 | Board Of Regents, The University Of Texas System | Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection |
-
2013
- 2013-07-05 EP EP13812631.3A patent/EP2870171B1/en active Active
- 2013-07-05 ES ES13812631.3T patent/ES2639121T3/es active Active
- 2013-07-05 US US16/662,518 patent/USRE48636E1/en active Active
- 2013-07-05 KR KR1020130079156A patent/KR101516791B1/ko active Active
- 2013-07-05 JP JP2015520069A patent/JP6404213B2/ja active Active
- 2013-07-05 WO PCT/KR2013/006009 patent/WO2014007584A1/en not_active Ceased
- 2013-07-05 US US14/413,005 patent/US10208085B2/en not_active Ceased
-
2018
- 2018-12-18 US US16/224,438 patent/US10479816B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012115277A5 (https=) | ||
| JP2018138049A5 (https=) | ||
| JP2010519252A5 (https=) | ||
| JP2018538356A5 (https=) | ||
| JP2015533791A5 (https=) | ||
| JP2010065046A5 (https=) | ||
| JP2015522576A5 (https=) | ||
| EP2594581A3 (en) | Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens | |
| RU2015120663A (ru) | Связывающие белки, содержащие, по меньшей мере, две повторяющиеся области-антагонисты HER2 | |
| JP2018505146A5 (https=) | ||
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2016531110A5 (https=) | ||
| JP2015521588A5 (https=) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| IL308112A (en) | An active dominant YAP gene, which activates HIPPO, causes chromatin accessibility and cardiac muscle cell renewal | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2006506942A5 (https=) | ||
| JP2014529399A5 (https=) | ||
| JP2012102105A5 (https=) | ||
| HK1245129A1 (zh) | 治疗腹腔疾病的组合物及方法 | |
| JP2015520178A5 (https=) | ||
| JP2016500647A5 (https=) | ||
| JP2019512004A5 (https=) | ||
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics |